The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer

Kozo Noguchi, Masamitsu Konno, Jun Koseki, Naohiro Nishida, Koichi Kawamoto, Daisaku Yamada, Tadafumi Asaoka, Takehiro Noda, Hiroshi Wada, Kunihito Gotoh, Daisuke Sakai, Toshihiro Kudo, Taroh Satoh, Hidetoshi Eguchi, Yuichiro Doki, Masaki Mori, Hideshi Ishii

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

The expression levels of one-carbon metabolic enzymes were investigated and observed to be correlated with clinicopathological parameters in patients with pancreatic cancer. Mitochondrial one-carbon metabolism comprises a network of biological reactions that integrate nutrient status with nucleotide synthesis, amino acid metabolism, antioxidant reduced nicotinamide adenine dinucleotide phosphate production and epigenetic methylation processes. Previous studies have reported that the hyper-activation of mitochondrial one-carbon metabolism serves a significant role in malignant cancer phenotypes. A total of 103 patients underwent surgical resection of pancreatic ductal adenocarcinomas (PDAC) at Osaka University Hospital between April 2007 and December 2013 and were enrolled in this study. Subsequently, the expression of the one-carbon metabolic enzymes methy-lenetetrahydrofolate dehydrogenase 2 (MTHFD2), aldehyde dehydrogenase 1 family member L2 (ALDH1L2), and serine hydroxymethyltransferase (SHMT2) was examined using immunohistochemical analysis. The immunohistochemical analyses demonstrated that patients with high expression levels of MTHFD2, ALDH1L2 or SHMT2 had significantly poor overall survival (OS) and disease-free survival (DFS) rates, as compared with patients with low expression levels. Furthermore, multivariate Cox proportional hazards analysis indicated that MTHFD2 and ALDH1L2 were independent prognostic factors for OS and DFS, whereas SHMT2 was not predictive of DFS. However, high and low expression levels of all three folate metabolic enzymes were significantly associated with improved OS and DFS, compared with the high expression of one or two folate metabolic enzymes. The expression levels of mitochondrial one-carbon metabolic enzymes are independent prognostic factors and potential therapeutic targets for future pancreatic cancer treatments.

Original languageEnglish
Pages (from-to)1827-1834
Number of pages8
JournalOncology Letters
Volume16
Issue number2
DOIs
Publication statusPublished - Aug 2018

Fingerprint

Metabolic Networks and Pathways
Pancreatic Neoplasms
Carbon
Disease-Free Survival
Survival
Enzymes
Oxidoreductases
Folic Acid
Glycine Hydroxymethyltransferase
Genetic Epigenesis
NADP
Methylation
Adenocarcinoma
Survival Rate
Nucleotides
Antioxidants
Phenotype
Amino Acids
Food
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Noguchi, K., Konno, M., Koseki, J., Nishida, N., Kawamoto, K., Yamada, D., ... Ishii, H. (2018). The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. Oncology Letters, 16(2), 1827-1834. https://doi.org/10.3892/ol.2018.8795

The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. / Noguchi, Kozo; Konno, Masamitsu; Koseki, Jun; Nishida, Naohiro; Kawamoto, Koichi; Yamada, Daisaku; Asaoka, Tadafumi; Noda, Takehiro; Wada, Hiroshi; Gotoh, Kunihito; Sakai, Daisuke; Kudo, Toshihiro; Satoh, Taroh; Eguchi, Hidetoshi; Doki, Yuichiro; Mori, Masaki; Ishii, Hideshi.

In: Oncology Letters, Vol. 16, No. 2, 08.2018, p. 1827-1834.

Research output: Contribution to journalArticle

Noguchi, K, Konno, M, Koseki, J, Nishida, N, Kawamoto, K, Yamada, D, Asaoka, T, Noda, T, Wada, H, Gotoh, K, Sakai, D, Kudo, T, Satoh, T, Eguchi, H, Doki, Y, Mori, M & Ishii, H 2018, 'The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer', Oncology Letters, vol. 16, no. 2, pp. 1827-1834. https://doi.org/10.3892/ol.2018.8795
Noguchi, Kozo ; Konno, Masamitsu ; Koseki, Jun ; Nishida, Naohiro ; Kawamoto, Koichi ; Yamada, Daisaku ; Asaoka, Tadafumi ; Noda, Takehiro ; Wada, Hiroshi ; Gotoh, Kunihito ; Sakai, Daisuke ; Kudo, Toshihiro ; Satoh, Taroh ; Eguchi, Hidetoshi ; Doki, Yuichiro ; Mori, Masaki ; Ishii, Hideshi. / The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer. In: Oncology Letters. 2018 ; Vol. 16, No. 2. pp. 1827-1834.
@article{291e92888ddf43ad91168ed283fb8ee4,
title = "The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer",
abstract = "The expression levels of one-carbon metabolic enzymes were investigated and observed to be correlated with clinicopathological parameters in patients with pancreatic cancer. Mitochondrial one-carbon metabolism comprises a network of biological reactions that integrate nutrient status with nucleotide synthesis, amino acid metabolism, antioxidant reduced nicotinamide adenine dinucleotide phosphate production and epigenetic methylation processes. Previous studies have reported that the hyper-activation of mitochondrial one-carbon metabolism serves a significant role in malignant cancer phenotypes. A total of 103 patients underwent surgical resection of pancreatic ductal adenocarcinomas (PDAC) at Osaka University Hospital between April 2007 and December 2013 and were enrolled in this study. Subsequently, the expression of the one-carbon metabolic enzymes methy-lenetetrahydrofolate dehydrogenase 2 (MTHFD2), aldehyde dehydrogenase 1 family member L2 (ALDH1L2), and serine hydroxymethyltransferase (SHMT2) was examined using immunohistochemical analysis. The immunohistochemical analyses demonstrated that patients with high expression levels of MTHFD2, ALDH1L2 or SHMT2 had significantly poor overall survival (OS) and disease-free survival (DFS) rates, as compared with patients with low expression levels. Furthermore, multivariate Cox proportional hazards analysis indicated that MTHFD2 and ALDH1L2 were independent prognostic factors for OS and DFS, whereas SHMT2 was not predictive of DFS. However, high and low expression levels of all three folate metabolic enzymes were significantly associated with improved OS and DFS, compared with the high expression of one or two folate metabolic enzymes. The expression levels of mitochondrial one-carbon metabolic enzymes are independent prognostic factors and potential therapeutic targets for future pancreatic cancer treatments.",
author = "Kozo Noguchi and Masamitsu Konno and Jun Koseki and Naohiro Nishida and Koichi Kawamoto and Daisaku Yamada and Tadafumi Asaoka and Takehiro Noda and Hiroshi Wada and Kunihito Gotoh and Daisuke Sakai and Toshihiro Kudo and Taroh Satoh and Hidetoshi Eguchi and Yuichiro Doki and Masaki Mori and Hideshi Ishii",
year = "2018",
month = "8",
doi = "10.3892/ol.2018.8795",
language = "English",
volume = "16",
pages = "1827--1834",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "2",

}

TY - JOUR

T1 - The mitochondrial one-carbon metabolic pathway is associated with patient survival in pancreatic cancer

AU - Noguchi, Kozo

AU - Konno, Masamitsu

AU - Koseki, Jun

AU - Nishida, Naohiro

AU - Kawamoto, Koichi

AU - Yamada, Daisaku

AU - Asaoka, Tadafumi

AU - Noda, Takehiro

AU - Wada, Hiroshi

AU - Gotoh, Kunihito

AU - Sakai, Daisuke

AU - Kudo, Toshihiro

AU - Satoh, Taroh

AU - Eguchi, Hidetoshi

AU - Doki, Yuichiro

AU - Mori, Masaki

AU - Ishii, Hideshi

PY - 2018/8

Y1 - 2018/8

N2 - The expression levels of one-carbon metabolic enzymes were investigated and observed to be correlated with clinicopathological parameters in patients with pancreatic cancer. Mitochondrial one-carbon metabolism comprises a network of biological reactions that integrate nutrient status with nucleotide synthesis, amino acid metabolism, antioxidant reduced nicotinamide adenine dinucleotide phosphate production and epigenetic methylation processes. Previous studies have reported that the hyper-activation of mitochondrial one-carbon metabolism serves a significant role in malignant cancer phenotypes. A total of 103 patients underwent surgical resection of pancreatic ductal adenocarcinomas (PDAC) at Osaka University Hospital between April 2007 and December 2013 and were enrolled in this study. Subsequently, the expression of the one-carbon metabolic enzymes methy-lenetetrahydrofolate dehydrogenase 2 (MTHFD2), aldehyde dehydrogenase 1 family member L2 (ALDH1L2), and serine hydroxymethyltransferase (SHMT2) was examined using immunohistochemical analysis. The immunohistochemical analyses demonstrated that patients with high expression levels of MTHFD2, ALDH1L2 or SHMT2 had significantly poor overall survival (OS) and disease-free survival (DFS) rates, as compared with patients with low expression levels. Furthermore, multivariate Cox proportional hazards analysis indicated that MTHFD2 and ALDH1L2 were independent prognostic factors for OS and DFS, whereas SHMT2 was not predictive of DFS. However, high and low expression levels of all three folate metabolic enzymes were significantly associated with improved OS and DFS, compared with the high expression of one or two folate metabolic enzymes. The expression levels of mitochondrial one-carbon metabolic enzymes are independent prognostic factors and potential therapeutic targets for future pancreatic cancer treatments.

AB - The expression levels of one-carbon metabolic enzymes were investigated and observed to be correlated with clinicopathological parameters in patients with pancreatic cancer. Mitochondrial one-carbon metabolism comprises a network of biological reactions that integrate nutrient status with nucleotide synthesis, amino acid metabolism, antioxidant reduced nicotinamide adenine dinucleotide phosphate production and epigenetic methylation processes. Previous studies have reported that the hyper-activation of mitochondrial one-carbon metabolism serves a significant role in malignant cancer phenotypes. A total of 103 patients underwent surgical resection of pancreatic ductal adenocarcinomas (PDAC) at Osaka University Hospital between April 2007 and December 2013 and were enrolled in this study. Subsequently, the expression of the one-carbon metabolic enzymes methy-lenetetrahydrofolate dehydrogenase 2 (MTHFD2), aldehyde dehydrogenase 1 family member L2 (ALDH1L2), and serine hydroxymethyltransferase (SHMT2) was examined using immunohistochemical analysis. The immunohistochemical analyses demonstrated that patients with high expression levels of MTHFD2, ALDH1L2 or SHMT2 had significantly poor overall survival (OS) and disease-free survival (DFS) rates, as compared with patients with low expression levels. Furthermore, multivariate Cox proportional hazards analysis indicated that MTHFD2 and ALDH1L2 were independent prognostic factors for OS and DFS, whereas SHMT2 was not predictive of DFS. However, high and low expression levels of all three folate metabolic enzymes were significantly associated with improved OS and DFS, compared with the high expression of one or two folate metabolic enzymes. The expression levels of mitochondrial one-carbon metabolic enzymes are independent prognostic factors and potential therapeutic targets for future pancreatic cancer treatments.

UR - http://www.scopus.com/inward/record.url?scp=85049463882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049463882&partnerID=8YFLogxK

U2 - 10.3892/ol.2018.8795

DO - 10.3892/ol.2018.8795

M3 - Article

AN - SCOPUS:85049463882

VL - 16

SP - 1827

EP - 1834

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 2

ER -